Christopher Fenimore - Regeneron Pharmaceuticals Vice President Controller

REGN -- USA Stock  

USD 286.15  1.09  0.38%

  President
Mr. Christopher Fenimore is Vice President, Controller of the Company. He was Vice President, Controller since March 2017. From January 2017 to March 2017, he served as Vice President, Deputy Controller, and previously served as Vice President, Financial Planning from January 2012 to December 2016. Prior to joining the Company in 2003, he was Vice President, Finance at Mojave Therapeutics, Inc. Mr. Fenimore prior experience includes working as a supervising senior accountant at KPMG, as well as healthcare industryfocused VC and investment banking roles. Mr. Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York.
Age: 47  President Since 2017  MBA    
914-847-7000  http://www.regeneron.com
Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University.

Christopher Fenimore Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Grainne QuinnPerrigo Company plc
2016
Ronald JanishPerrigo Company plc
2015
Amit SachdevVertex Pharmaceuticals Incorpor
2017
Alejandro BernalZoetis
2015
John GrayVertex Pharmaceuticals Incorpor
2019
Michael PariniVertex Pharmaceuticals Incorpor
2017
Alok SonigDr Reddys Laboratories Ltd
2015
Sandra BeatyZoetis
2012
Scott JamisonPerrigo Company plc
2011
Heidi ChenZoetis
2012
Catherine KnuppZoetis
2012
Michael StewartPerrigo Company plc
2004
Marc CouckePerrigo Company plc
N/A
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Thomas FarringtonPerrigo Company plc
2015
Paul WeningerPerrigo Company plc
2015
John HendricksonPerrigo Company plc
2016

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

FB   
Purchased few shares of
few hours ago
Traded for 188.14
VMW   
Purchased a lot of shares of
few hours ago
Traded for 150.35
V   
Purchased few shares of
few hours ago
Traded for 175.29
CRM   
Purchased a lot of shares of
few hours ago
Traded for 152.77
F   
Purchased over 300 shares of
few hours ago
Traded for 9.25
Additionally take a look at Your Equity Center. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Search macroaxis.com